Keyphrases
μ-opioid Receptor
100%
Advanced Prostate Cancer
100%
Opioid Receptor Expression
100%
Clinical Outcomes
100%
Opioid Requirements
100%
Confidence Interval
83%
Hazard Ratio
83%
Opioids
50%
Overall Survival
50%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
33%
Progression-free Survival
33%
Validation Cohort
33%
Minneapolis
16%
Disease Progression
16%
Opioid Use
16%
Prospective Randomized Trial
16%
Prostate Cancer
16%
Angiogenesis
16%
Clinical Practice
16%
Tumor Progression
16%
Cancer Progression
16%
Variable Effect
16%
Cancer Registry
16%
Retrospective Analysis
16%
Chronic Opioids
16%
Tumor Registry
16%
Multivariable Model
16%
Immunoreactivity
16%
Laser Scanning Confocal Microscopy
16%
Cancer-specific Survival
16%
Abrogation
16%
Human Malignancies
16%
Peripheral Activity
16%
Disease Survival
16%
Prostate Cancer Biopsy
16%
Oral Morphine Equivalent
16%
Medicine and Dentistry
Prostate Cancer
100%
Receptor Expression
100%
μ-Opioid Receptor
100%
Opioid Receptor
100%
Hazard Ratio
83%
Overall Survival
50%
Progression Free Survival
33%
Neoplasm
16%
Disease Exacerbation
16%
Cancer
16%
Tumor Progression
16%
Cancer Growth
16%
Cancer Survival
16%
Cancer Registry
16%
Identified Patient
16%
Immunoreactivity
16%
Angiogenesis
16%
Confocal Laser Scanning Microscopy
16%
Tumor Biopsy
16%
Morphine
16%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Opiate Receptor
100%
μ-Opioid Receptor
100%
Overall Survival
50%
Progression Free Survival
33%
Preclinical Study
16%
Confocal Microscopy
16%
Cancer Registry
16%
Disease Exacerbation
16%
Tumor Growth
16%
Cancer Survival
16%
Cancer Growth
16%
Morphine
16%
Neoplasm
16%